Form 4: Axsome Therapeutics Executive Hunter R. Murdock Reports Stock Option and Unit Awards

Hunter R. Murdock, General Counsel of Axsome Therapeutics, reports the acquisition of stock options, restricted stock units (RSUs), and performance stock units (PSUs).

Summary

• Hunter R. Murdock, General Counsel of Axsome Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 21, 2025, Murdock was granted employee stock options for 7,816 shares at an exercise price of $137.75, vesting quarterly over four years.
• He also received 7,740 restricted stock units (RSUs) which vest over four years, with 25% vesting after one year and the remainder in three equal annual installments.
• Vested RSU shares will be delivered upon a Change in Control, separation of service, or seven years from the grant date.
• Additionally, Murdock was granted 7,740 performance stock units (PSUs) on February 24, 2025, which vest upon achievement of certain performance milestones.
• Murdock directly owns 7,816 shares underlying the options, 7,740 shares underlying the RSUs, and 7,740 shares underlying the PSUs.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance and alignment of executive interests with shareholder value. The sentiment is neutral to positive.

Positives

• The grant of stock options, RSUs, and PSUs aligns Murdock's interests with the long-term success of Axsome Therapeutics.
• The vesting schedules for the options and RSUs incentivize continued service and commitment to the company.
• The performance-based vesting of PSUs ties executive compensation to the achievement of specific financial, regulatory, and developmental goals.

Risks

• The value of the stock options, RSUs, and PSUs is dependent on the future performance of Axsome Therapeutics' stock.
• Failure to achieve the performance milestones required for PSU vesting could result in Murdock not receiving the full potential value of the grant.
• Changes in control or separation of service could impact the timing of RSU share delivery.

Future Outlook

The vesting of the stock options, RSUs, and PSUs is contingent upon continued service and, in the case of PSUs, the achievement of specific performance milestones. The value of these awards will depend on the future performance of Axsome Therapeutics.

Industry Context

Stock option and unit grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The specific terms of these grants, such as vesting schedules and performance milestones, are tailored to the company's specific goals and circumstances.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options, RSUs, and PSUs to align executive incentives with shareholder value.
• Vesting schedules and performance metrics vary across companies, reflecting different strategic priorities and risk profiles.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value.
• Employees: The grants can boost employee morale by demonstrating investment in leadership.
• Executives: The grants provide incentives for achieving company goals.

Key Dates